Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Common Equity (2016 - 2025)

Historic Common Equity for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $631.9 million.

  • Corcept Therapeutics' Common Equity fell 108.53% to $631.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $631.9 million, marking a year-over-year decrease of 108.53%. This contributed to the annual value of $679.6 million for FY2024, which is 3411.93% up from last year.
  • Corcept Therapeutics' Common Equity amounted to $631.9 million in Q3 2025, which was down 108.53% from $635.8 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Common Equity high stood at $683.3 million for Q1 2025, and its period low was $375.8 million during Q4 2021.
  • Its 5-year average for Common Equity is $532.0 million, with a median of $522.7 million in 2021.
  • As far as peak fluctuations go, Corcept Therapeutics' Common Equity crashed by 2819.06% in 2021, and later soared by 4141.92% in 2024.
  • Over the past 5 years, Corcept Therapeutics' Common Equity (Quarter) stood at $375.8 million in 2021, then skyrocketed by 33.54% to $501.8 million in 2022, then increased by 0.97% to $506.7 million in 2023, then skyrocketed by 34.12% to $679.6 million in 2024, then dropped by 7.02% to $631.9 million in 2025.
  • Its Common Equity stands at $631.9 million for Q3 2025, versus $635.8 million for Q2 2025 and $683.3 million for Q1 2025.